XOMA’s (XOMA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research note released on Thursday, Benzinga reports. The brokerage currently has a $74.00 price target on the biotechnology company’s stock.

XOMA Price Performance

Shares of XOMA opened at $25.41 on Thursday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 8.68 and a current ratio of 8.68. The stock has a 50 day simple moving average of $24.91 and a 200 day simple moving average of $20.48. XOMA has a 52-week low of $13.48 and a 52-week high of $27.00. The firm has a market capitalization of $295.77 million, a PE ratio of -6.29 and a beta of 0.58.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The firm had revenue of $1.83 million for the quarter, compared to analyst estimates of $1.01 million. Sell-side analysts predict that XOMA will post -1.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in XOMA stock. Barclays PLC bought a new position in shares of XOMA Co. (NASDAQ:XOMA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,468 shares of the biotechnology company’s stock, valued at approximately $28,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.